eprosartan (Teveten)

09/01/1999 - "In the recommended dose range of 600 to 1200 mg once daily, eprosartan is effective in patients with all grades of hypertension irrespective of age, sex, or race. "
06/01/1999 - "When taken in the recommended dose range, 600-800 mg once daily, eprosartan is effective in patients with all grades of hypertension, regardless of age, sex or race. "
01/01/2002 - "Monotherapy with eprosartan mesilat was effective in all patients with moderate arterial hypertension and in 43.6% in patients with severe arterial hypertension. "
01/01/2009 - "Eprosartan also reduced blood pressure and was associated with a modest improvement in cognitive function in a large observational study in patients > or =50 years of age with newly diagnosed hypertension (OSCAR study). "
01/01/2006 - "One hundred drivers with arterial hypertension were included into the study and 2 adequate groups were distinguished: 1st which consisted of 50 persons receiving eprosartan (600 mg/day), and 2nd which comprised 50 persons receiving placebo. "

06/01/2001 - "These data demonstrate that eprosartan, at a clinically relevant dose, provides significant end-organ protection in the severely hypertensive stroke-prone rat. "
01/01/2002 - "Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. "
03/01/2007 - "Eprosartan in secondary prevention of stroke: the economic evidence."
11/01/2007 - "Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline."
01/01/2003 - "Twenty patients with stroke of hemisphere localization developed as a result of arterial hypertension were treated with eprosartan mesilat. "

01/01/2001 - "Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension."
01/01/2001 - "This open-label study was designed to investigate the long-term safety and efficacy of the AT1 receptor blocker, eprosartan, in patients with mild to moderate essential hypertension (sitting diastolic blood pressure > or = 95 mmHg and < or = 114 mmHg). "
10/01/2004 - "The present study was an observational study of 4067 patients (55% women, mean age 67 years) with essential hypertension, newly diagnosed or unresponsive to current treatment, in which 3133 patients received 12 weeks of treatment with eprosartan 600 mg/day (87% monotherapy) in primary care centres. "
01/01/2016 - "To improve our understanding of renal AT1Rs in hypertensive patients, we studied the effects of acute, local administration of AT1R-blocker eprosartan in kidneys of patients with essential hypertension (off medication). "
01/01/2007 - "This open-label unblinded intervention study included 40 adult patients with essential hypertension taking eprosartan. "

11/01/2007 - "In clinical trials, eprosartan has been shown to significantly reduce systolic blood pressure and to be associated with significant reductions in pulse pressure in elderly patients with isolated systolic hypertension. "
09/01/2004 - "This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension. "
11/01/2007 - "Of importance to isolated systolic hypertension, trough sitting systolic blood pressure (SBP) is also significantly reduced with eprosartan. "
12/01/2004 - "Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension."
11/01/1997 - "Because eprosartan is more effective in inhibiting sympathetic nervous system activity compared to other chemically distinct nonpeptide angiotensin II receptor antagonists, eprosartan may be more effective in lowering systolic blood pressure and in treating isolated systolic hypertension."

06/01/2005 - "[Effect of a combination of teveten and prestarium in patients with chronic heart failure]."
10/01/1998 - "Moreover, eprosartan caused a preferential increase in renal cortical blood perfusion and significantly increased glomerular filtration in rats with congestive heart failure. "
01/01/2003 - "1. We examined the effects of eprosartan, an AT(1) receptor antagonist, on the progression of left ventricular (LV) dysfunction and remodelling in dogs with heart failure (HF) produced by intracoronary microembolizations (LV ejection fraction, EF 30 to 40%). "
01/01/2003 - "Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure."
10/01/1998 - "Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure."